Discovery Minerals LTD (DSCR): Yea, I guess North Bay is next door to D...

$PennyMover · 2024-08-23T17:17:01.4000000Z

Yea, I guess North Bay is next door to DSCR. Be nice to get back to being open and trading but we sit and wait...smh

Play Episode

5min

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Sintana Energy advances Orange Basin portfolio with key exploration updates

Sintana Energy CEO Robert Bose recently spoke with Steve Darling from Proactive to provide a comprehensive update on the company’s Orange Basin assets, highlighting significant progress across PEL 83, PEL 90, PEL 87, and PEL 82. Bose sahred positive results from the Mopane 3-X well on PEL 83, operated by Galp. The well, which targeted new AVO anomalies 10 and 13, delivered better-than-expected results across nearly every parameter, confirming the presence of high-quality oil and condensate. This discovery has the potential to establish a new development hub, positioning PEL 83 as a key asset in the basin. Moving forward, activity will focus on evaluating partnership opportunities, with Galp expected to seek new partners in the coming quarters. The first Chevron-operated well on PEL 90 did not encounter commercial hydrocarbons but was still regarded as a technical success. Bose emphasized the company’s confidence in the exploration potential of the block, noting that the joint venture partners plan to return for further drilling later this year. Bose also provided an update on PEL 87’s Saturn Superfan prospect, where Woodside Energy chose not to proceed after completing a 3D seismic survey. Despite this, Sintana remains highly optimistic and is now in discussions with alternative supermajor partners. “We’re very excited about opening up the doors to larger, potential partners,” Bose stated, highlighting the continued confidence in the asset’s potential. Chevron has officially completed its farm-in at PEL 82, located in the Walvis Basin, paving the way for drilling operations next year. Bose also pointed to the growing political support for oil and gas development in Namibia, with upstream regulatory oversight now moved directly under the President’s office—a move he called “a huge step forward” for the industry. This shift reinforces the government’s commitment to fostering a thriving energy sector that could significantly contribute to national GDP growth. #pro

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	391
Posts	26015
Boards Moderated	2
Alias Born	01/23/2002

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

DSCR Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free